About cancerBreast cancerColorectal cancerLung cancerRenal cell cancerClinical casesExpert reviewsHighlightsProduct informationNewsWebcasts
Home
Site Map
Avastin®
Herceptin®
Breast cancer HER 2+
About Herceptin®
Herceptin® development
Administration
Efficacy
Adjunvant efficacy
HERA Trial
NCCTG N9831 Trial
NSABP B-31 Trial
BCIRG 006 Trial
Neoadjuvant efficacy
Metastasic breast cancer efficacy
Safety
Cardiac safety
Dosage
Mabthera®
Tarceva®
Xeloda®
Home/EN/Product information/Herceptin®/Efficacy/Adjunvant efficacy/BCIRG 006 Trial
BCIRG 006 Trial 
Add to favorites Print preview Recommend this page to a colleague

A global, Phase III, randomised, multicentre, open-label trial of 1 year of adjuvant Herceptin given with chemotherapy compared with chemotherapy alone in HER2-positive EBC.

BCIRG 006 trial
 
 
Privacy Policy | Legal Statement
The information on this Web site is intended only for visitors from Aruba, Bahamas, Barbados, Bermuda, Curacao, Jamaica, St. Maarten, St. Lucia and Trinidad & Tobago
All rights reserved © 2008 F. Hoffmann-La Roche Ltd.